EN106

EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. EN106 reduces oxidative stress and rescues high glucose-induced impaired angiogenesis in HUVECs[1][2].

Product Specifications

CAS Number

[757192-67-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

E1/E2/E3 Enzyme; NF-κB; Reactive Oxygen Species (ROS) ; SOD

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/en106.html

Purity

99.92

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N(CCC#N)C1=CC=C(OCCO2)C2=C1)CCl

Molecular Formula

C13H13ClN2O3

Molecular Weight

280.71

Precautions

H302, H315, H319, H335

References & Citations

[1]Henning NJ, et al. Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications. J Am Chem Soc. 2022;144 (2) :701-708.|[2]Zhang W, et al., Glucose-responsive, antioxidative HA-PBA-FA/EN106 hydrogel enhanced diabetic wound healing through modulation of FEM1b-FNIP1 axis and promoting angiogenesis. Bioact Mater. 2023 Jul 22;30:29-45.